Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVJF) Long-Term Debt Repayments (2017 - 2025)

Historic Long-Term Debt Repayments for Teva Pharmaceutical Industries (TEVJF) over the last 11 years, with Q3 2025 value amounting to $444.0 million.

  • Teva Pharmaceutical Industries' Long-Term Debt Repayments changed N/A to $444.0 million in Q3 2025 from the same period last year, while for Dec 2025 it was $4.1 billion, marking a year-over-year increase of 15057.89%. This contributed to the annual value of $4.1 billion for FY2025, which is 15057.89% up from last year.
  • Teva Pharmaceutical Industries' Long-Term Debt Repayments amounted to $444.0 million in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Long-Term Debt Repayments ranged from a high of $5.2 billion in Q4 2021 and a low of $296.0 million during Q2 2022
  • Over the past 5 years, Teva Pharmaceutical Industries' median Long-Term Debt Repayments value was $978.0 million (recorded in 2023), while the average stood at $1.5 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Long-Term Debt Repayments tumbled by 8631.62% in 2022 and then skyrocketed by 17397.26% in 2023.
  • Teva Pharmaceutical Industries' Long-Term Debt Repayments (Quarter) stood at $5.2 billion in 2021, then crashed by 86.32% to $708.0 million in 2022, then surged by 41.24% to $1.0 billion in 2023, then plummeted by 31.5% to $685.0 million in 2024, then crashed by 35.18% to $444.0 million in 2025.
  • Its Long-Term Debt Repayments was $444.0 million in Q3 2025, compared to $2.3 billion in Q2 2025 and $1.4 billion in Q1 2025.